Myotonic Dystrophy Type 1 (DM1) Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1
The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 4 periods: A Screening Period (up to 8 weeks), a multiple-ascending dose (MAD) Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (96 weeks).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05027269 -
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04835298 -
Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1
|
||
| Completed |
NCT03589677 -
Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life
|
||
| Recruiting |
NCT05560438 -
Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1
|
N/A | |
| Recruiting |
NCT06185764 -
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05072288 -
A Remote Physical Activity Program in the Population Suffering From Type 1 Myotonic Dystrophy
|
N/A | |
| Completed |
NCT04907162 -
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
|